Nazartinib一线治疗EGFR突变非小细胞肺癌:一项2期单臂开放标签研究结果
这项全球单臂开放标签2期研究纳入45例初治EGFR突变IIIB/IV期非小细胞肺癌患者,口服nazartinib 150 mg每日一次。BIRC评估的ORR为69%(95%CI 53-82),中位PFS为18个月(95%CI 15-不可估计),基线脑转移患者ORR为67%、中位PFS为17个月,安全性可控。
要点
- 初治EGFR突变NSCLC患者接受nazartinib 150 mg每日一次,BIRC评估ORR达69%。
- 中位PFS为18个月(95%CI 15-不可估计),中位OS不可估计。
- 基线脑转移患者ORR为67%,17例可评估中枢病灶中9例(53%)病灶消失或正常化。
核心结论
- 一线nazartinib在EGFR突变NSCLC中显示出有前景的疗效,包括具有临床意义的中枢抗肿瘤活性,且安全性可控。
研究设计与样本
- 全球、单臂、开放标签2期研究,纳入初治成人IIIB/IV期EGFR活化突变(如L858R和/或ex19del)NSCLC患者,允许神经学稳定且受控的脑转移患者入组。
主要发现
- 45例患者接受至少1剂nazartinib,从入组至数据截止(2019年11月1日)的中位随访时间为30个月(范围25-34)。
- BIRC评估的ORR为69%(95%CI 53-82),中位PFS为18个月(95%CI 15-不可估计),中位OS不可估计。
- 基线脑转移患者(n=18)的ORR为67%(95%CI 41-87),中位PFS为17个月(95%CI 11-21)。
- 18例基线脑转移患者中17例脑转移为非靶病灶,其中9/17(53%)中枢病灶消失或正常化;无基线脑转移的27例患者中仅2例在基线后出现新发脑转移。
- 最常见不良事件(≥25%,任何级别,全因)为腹泻(47%)、斑丘疹(38%)、发热(29%)、咳嗽和口腔炎(各27%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Nazartinib, a novel third-generation EGFR-tyrosine kinase inhibitor, previously demonstrated antitumor activity and manageable safety in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) who received ≤ 3 prior lines of systemic therapy. Herein, we report phase 2 efficacy and safety of first-line nazartinib. METHODS: This single-arm, open-label, global study enrolled treatment-naive adult patients with stage IIIB/IV NSCLC harboring EGFR-activating mutations (eg, L858R and/or ex19del). Patients with neurologically stable and controlled brain metastases were also eligible. Patients received oral nazartinib 150 mg once daily. The primary endpoint was Blinded Independent Review Committee (BIRC)-assessed overall response rate (ORR) per RECIST v1.1. RESULTS: Forty-five patients received ≥ 1 dose of nazartinib. The median follow-up time from enrollment to data cutoff (November 1, 2019) was 30 months (range: 25-34). The BIRC-assessed ORR was 69% (95% CI, 53-82). The median progression-free survival (PFS) was 18 months (95% CI, 15-not estimable [NE]). The median overall survival was NE. In patients with baseline brain metastases (n = 18), the ORR and median PFS (95% CIs) were 67% (41-87) and 17 months (11-21). Seventeen of 18 patients had brain metastases as non-target lesions; the CNS lesions were absent/normalized in 9 of 17 (53%). Only 2 of 27 patients without baseline brain metastases developed new brain metastases postbaseline. Most frequent adverse events (≥ 25%, any grade, all-causality) were diarrhea (47%), maculopapular rash (38%), pyrexia (29%), cough, and stomatitis (27% each). CONCLUSIONS: First-line nazartinib demonstrated promising efficacy, including clinically meaningful antitumor activity in the brain, and manageable safety in patients with EGFR-mutant NSCLC. TRIAL REGISTRATION: ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02108964.
引用
- Tan DSW, Kim SW, Ponce Aix S, et al. Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study. Eur J Cancer. 2022. PMID: 35810553. doi:10.1016/j.ejca.2022.05.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。